dihydroartemisinin-piperaquine (DHA-PQP)

DRUG2 trials

Sponsors

GlaxoSmithKline, London School of Hygiene and Tropical Medicine

Conditions

Cardiac SafetyCardiotoxicityMalariaMalaria, VivaxParasitemiaPregnancy Malaria

Phase 2

Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania

CompletedNCT02909712

London School of Hygiene and Tropical MedicineCardiac Safety, Cardiotoxicity, Malaria +2

Start: 2016-09-30End: 2020-02-29Updated: 2021-02-02

Phase 3

Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

CompletedNCT02802501

GlaxoSmithKlineMalaria, Vivax

Start: 2018-04-08End: 2019-08-19Updated: 2020-07-24

Related Papers

Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.

2023-05-2336 citations

Single-Dose Tafenoquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria

New England Journal of Medicine2019-01-16277 citations

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria

PLoS ONE2017-11-0936 citations